SMARCB1 and cancer: The IC50 (50% inhibitory concentration) values derived from JMU-RTK-2 -SMARCB1 cells treated with CBP/p300-specific inhibitors CP-C27, A-485, and inobrodib were markedly lower than those from JMU-RTK-2 +SMARCB1 cells and HEK293T non-cancer cells (Fig. 1j).